Elemental Impurities

Ensuring compliance with ICH Q3D Guidelines

Elemental impurities in medicinal products pose significant risks to patient safety and regulatory compliance. At QbD Group, we provide expert support for analyzing, controlling, and mitigating elemental impurities in accordance with ICH Q3D guidelines. Using state-of-the-art techniques, we help you achieve compliance while ensuring the safety and efficacy of your products.

Discover how we can help you

Get in touch

ICP-MS analyses

State-of-the-art testing for elemental impurities and heavy metals with low detection limits.

Risk assessments

Evaluating potential sources of elemental impurities in your processes and materials.

Control strategies

Implementing effective plans to manage and mitigate elemental impurities.

Accredited lab services

Offering reliable and efficient testing with clear cost visibility upfront.

Elemental Impurities - Lab Services - QbD Group (2)

Why partner with QbD Group?

QbD Group provides unmatched expertise and tailored solutions for managing elemental impurities:

Expert knowledge: In-depth understanding of ICH Q3D guidelines and pharmacopoeial standards.
Advanced technology: Cutting-edge ICP-MS equipment for precise and reliable results.
Efficient processes: Fast turnaround times and transparent cost structures.
Comprehensive support: From risk assessment to routine testing, we handle every aspect.
Proactive solutions: Guidance on best practices to maintain compliance and product quality.

What are elemental impurities?

Elemental impurities are trace levels of metals that can be introduced into medicinal products during manufacturing, packaging, or storage.

These impurities must be carefully monitored and controlled to meet stringent regulatory requirements and ensure product safety. Key aspects of elemental impurities include:

ICH Q3D compliance: Adherence to International Council for Harmonisation (ICH) guidelines for controlling elemental impurities.
Testing methods: Conducting analyses using pharmacopoeia procedures, such as ICP-MS (Inductively Coupled Plasma Mass Spectrometry).

Why is monitoring them essential?

Elemental impurity monitoring is crucial for:

Patient safety: Minimizes toxic risks associated with heavy metals.
Regulatory compliance: Meets ICH Q3D and pharmacopoeial requirements.
Risk mitigation: Identifies sources of elemental impurities during risk assessments.
Product quality: Ensures the integrity of both raw materials and finished products.
Streamlined operations: Avoids delays or rejections due to non-compliance.

Get in touch

Ready to control elemental impurities in your products?

Ensure compliance with ICH Q3D guidelines and protect your product’s quality with QbD Group’s elemental impurities services. Contact us today to discuss your project and learn how we can support your testing and control needs.

Related content

Whitepaper

Digitalization in the Pharmaceutical Industry: And How to Stay Compliant

Digitalization and Pharma 4.0 drive digital transformation. Explore the role of CSV in pharma's digital journey.

Whitepaper

The Essential CSV & Digitalization FAQ for Life Sciences Companies

Get clear answers to real CSV questions from clients & experts. Download our FAQ and stay compliant, audit-ready, and confident in your Software Validation Strategy.

Whitepaper

Audit Trail Review in GxP Environments

Learn how to implement a risk-based Audit Trail review strategy to enhance software compliance in GxP environments.

Case study

Validating a Complex Autoclave Load to Enhance Sterilization Efficiency

Discover how QbD Group helped a pharmaceutical facility in Barcelona optimize and validate a complex autoclave load, improving sterilization efficiency and manufacturing flexibility.

Webinar

Pharmacovigilance and Risk Management in Innovative Therapies: A Challenge in Drug Safety

Explore pharmacovigilance in cell, CAR T, and RNA therapies. Join our webinar to tackle tomorrow’s drug safety and risk management challenges.

Webinar

Extractables & Leachables in Pharma: Navigating Evolving Regulations and Toxicological Challenges

This webinar aims to provide a comprehensive overview of Extractables and Leachables (E&L) in pharmaceutical products, highlighting regulatory complexities, toxicological challenges, and practical approaches to study design and risk assessment across the product lifecycle.

Whitepaper

A Complete Guide to Computer System Validation

This guide aims to bring context and define the necessary and appropriate strategies for the validation of computerized systems. Download now.

Whitepaper

Digital Health - Exploring the landscape and future opportunities

This whitepaper informs you about digital health, key technology pillars, and new opportunities to anticipate future trends in your healthcare sector.

Case study

A Decade of Excellence: Linguistic Review Support for a Global Pharma Leader

QbD Group streamlines linguistic reviews for a leading pharma client, ensuring compliance and accuracy across 25 EU/EEA languages while meeting stringent regulatory deadlines.

Whitepaper

ICH Stability Studies on Pharmaceuticals

This whitepaper discusses the importance of different methods for testing the stability of pharmaceutical products, stability study guidelines, and other aspects related to the stability of pharmaceutical products.

Whitepaper

EU GMP: How to import your products into the EU?

Are you a medicinal product manufacturer looking to import your products into the EU in line with the latest EU-GMP import regulations? Download our guide.

Case study

Scalable MSAT validation support for seamless compliance & efficiency

Discover how QbD Group helped a global pharmaceutical company address fluctuating validation demands across multiple teams.

Case study

Restoring manufacturing timelines through expert deviation management

Discover how QbD Group helped a leading biotechnology company overcome a backlog of deviations, restoring timely batch release through expert QA support.

Case study

Guiding a global biotech company through ATMP facility qualification

Discover how QbD Group supported a global biotech company in commissioning and qualifying two ATMP therapy production sites, ensuring compliance and efficiency.

Whitepaper

How to keep computerized systems in the operational phase

Ensure compliance and efficiency with best practices for maintaining computerized systems in the operational phase. Download our expert whitepaper now!

Whitepaper

Regulatory Affairs for Pharma and Biotech

In this flyer, you will learn more about the regulatory services QbD Group provides for the pharmaceutical and biotechnology industries.

Webinar

Drug-Device Combination Products and Article 117

Explore the regulatory complexities of Drug-Device Combination Products. Learn about Article 117 requirements, Notified Body Opinions, and more.

Webinar

Unlocking Strategic Value in Drug Safety for Life Sciences Organizations

Explore how drug safety teams can transform into proactive benefit drivers with the right tools & resources in this webinar on demand.

Whitepaper

GAMP 5 Software Validation Approach for GMP, GCP and GLP regulations

Learn how to comply with GMP, GCP, and GLP regulations using the GAMP 5 Software Validation Approach. Download the whitepaper for more insights.

Webinar

How to manage mandatory communication of Toxicological Risks?

Learn how to effectively manage toxicological risks in the pharmaceutical industry by addressing, reporting, and mitigating potential harm.

Webinar

Setting up ATMP Quality Management Systems: Strategies for Compliance and Success

Discover strategies for establishing a compliant and successful ATMP Quality Management System. Watch our webinar on demand.

Webinar

The Basic Concepts of the QbD Methodology

Learn the basics of QbD methodology with industry experts in this on-demand webinar.

Webinar

ATMP Supply Chain: Navigating the Challenges and Exploring the Vein-to-Vein Strategy

Explore the transformative ATMP journey and vein-to-vein strategy in our webinar. Learn how to navigate challenges and unlock the full potential of ATMPs.

Whitepaper

Achieving laboratory compliance

This whitepaper explores the multifaceted aspects of laboratory compliance, including data integrity, quality control measures, and regulatory adherence.

Whitepaper

Annual Product Quality Review in Pharma

Want to learn more about the importance, benefits, and key challenges related to the Annual Product Quality Review in Pharma? Then read on quickly!

Whitepaper

New GMP Facility Qualification: set-up, process and best practices

This whitepaper delves into the challenges of establishing a new GMP facility, focusing on potential pitfalls and best practices. Download now.

Whitepaper

The One-Vigilance strategic roadmap to corporate excellence

This whitepaper introduces the concept of One Vigilance within the context of the current drug safety landscape. Download now.

Case study

Guiding KU Leuven's glioblastoma research to the clinic with precision business planning

Helping KU Leuven advance glioblastoma research to the clinic with strategic business planning, funding support, and a roadmap for clinical impact.

Whitepaper

21 CFR Part 11 compliance checklist

Want to assess whether a computer system generates electronic records and uses electronic signatures, and whether the system complies with Part 11 of 21 CFR? Download this free checklist.

Whitepaper

Ensuring compliance and quality in Pharmacovigilance

The whitepaper emphasizes the importance of a robust pharmacovigilance QMS and a well-maintained Pharmacovigilance System Master File (PSMF). Download now.

Webinar

Second edition of GAMP 5: A Risk-Based Approach to compliant GxP Computerized Systems

This webinar on demand will tell you more about the second edition of GAMP 5.

Whitepaper

Organic and mutagenic impurities in pharma

Ensure pharmaceutical quality and safety by controlling organic and mutagenic impurities. Download this whitepaper to learn more.

Whitepaper

The key role of Regulatory Affairs in the pharmaceutical industry: from drug development to commercialization

Discover the key role of Regulatory Affairs in pharma and how Regulatory Affairs teams support product lifecycle management in this whitepaper. Download now.

Whitepaper

GAMP categories for computerized systems: what are they and what are they for?

In this whitepaper, you will learn what GAMP is, what GAMP categories are for, and where to start if you are facing computerized systems validation.

Whitepaper

Analytical Method Validation

In this whitepaper, we will give an overview of the criteria to consider when validating your analytical method.

Whitepaper

EUDRALEX Volume 4 Annex 11 Compliance Checklist

Assess your computer system's compliance with EudraLex Volume 4 Annex 11 guidelines using our checklist. Download now for GMP assurance.

Whitepaper

From V-model to Agile: how to embrace automation as part of the computerized system validation approach

This white paper explores why IT is shifting to agile, focuses on the prevalent Scrum methodology, and concludes with guidance on adapting system validation processes.

Whitepaper

Innovations in ATMP: state of the industry in 2024

This whitepaper explores the innovations in ATMP and solutions in detail, with a focus on the current landscape as of April 2024. Download now.

Case study

Optimizing pharmacovigilance for a biotechnology leader

Discover how QbD Group improved pharmacovigilance for a global leader in biotechnology, ensuring regulatory compliance and patient safety.

Case study

Ensuring timely launch: QbD Group's role in establishing a hemophilia drug production line

QbD Group has facilitated the launch of a new drug production line for treating hemophilia, overseeing the qualification of over 100 pieces of small-scale supporting equipment.

Case study

Ensuring pharmaceutical production quality: cleaning validation for government agency

Discover how QbD Group helped a client tackle dual validation challenges for their production lines, ensuring GMP compliance and AEMPS approval.

Case study

Revolutionizing pharmacovigilance: a success story of strategic partnership and seamless integration

Discover how QbD Group's expert support enhanced a pharmaceutical company's pharmacovigilance, leading to a favorable inspection outcome by the local Regulatory Authority (AEMPS).

Case study

Patient Support Program (PSP)

Learn about our patient support program (PSP) and how it helps manage customer support for a PV Spanish client. Resolve quality issues and ensure stability with QbD Pharma.

Blog

IVDR Compliance for Large-Panel Next-Generation Sequencing (NGS) Devices: A Strategic Guide

Next-Generation Sequencing (NGS) has revolutionized precision...

Blog

Patient Enrolment and Retention in Clinical Trials: How to Improve Recruitment and Keep Patients Engaged

In clinical research, the success of a trial heavily depends on two key...

Blog

Clinical Trial Site Selection and Qualification: A Practical Guide

Effective site selection and qualification are the cornerstones of any...

Blog

Risk Management in Clinical Trials: Assessment & Mitigation Strategies

Picture this: you’re racing to get a promising new therapy from lab bench to...

Blog

Establishing and Maintaining the Right Level of Clinical Evidence under the EU IVDR

We’re proud to highlight a new publication by Pieter Bogaert, PhD—senior...

Discover all

Elemental Impurities

How can we help?

ICP-MS analyses

ICP-MS analyses

Risk assessments

Risk assessments

Control strategies

Control strategies

Accredited lab services

Accredited lab services

Why partner with QbD Group?

What are elemental impurities?

Why is monitoring them essential?

What are elemental impurities?

Why is monitoring them essential?

Get in touch

Related content

Digitalization in the Pharmaceutical Industry: And How to Stay Compliant

The Essential CSV & Digitalization FAQ for Life Sciences Companies

Audit Trail Review in GxP Environments

Validating a Complex Autoclave Load to Enhance Sterilization Efficiency

Pharmacovigilance and Risk Management in Innovative Therapies: A Challenge in Drug Safety

Extractables & Leachables in Pharma: Navigating Evolving Regulations and Toxicological Challenges

A Complete Guide to Computer System Validation

Digital Health - Exploring the landscape and future opportunities

A Decade of Excellence: Linguistic Review Support for a Global Pharma Leader​

ICH Stability Studies on Pharmaceuticals

EU GMP: How to import your products into the EU?

Scalable MSAT validation support for seamless compliance & efficiency

Restoring manufacturing timelines through expert deviation management

Guiding a global biotech company through ATMP facility qualification

How to keep computerized systems in the operational phase

Regulatory Affairs for Pharma and Biotech

Drug-Device Combination Products and Article 117

Unlocking Strategic Value in Drug Safety for Life Sciences Organizations

GAMP 5 Software Validation Approach for GMP, GCP and GLP regulations

How to manage mandatory communication of Toxicological Risks?

Setting up ATMP Quality Management Systems: Strategies for Compliance and Success

The Basic Concepts of the QbD Methodology

ATMP Supply Chain: Navigating the Challenges and Exploring the Vein-to-Vein Strategy

Achieving laboratory compliance

Annual Product Quality Review in Pharma

New GMP Facility Qualification: set-up, process and best practices

The One-Vigilance strategic roadmap to corporate excellence

Guiding KU Leuven's glioblastoma research to the clinic with precision business planning

21 CFR Part 11 compliance checklist

Ensuring compliance and quality in Pharmacovigilance

Second edition of GAMP 5: A Risk-Based Approach to compliant GxP Computerized Systems

Organic and mutagenic impurities in pharma

The key role of Regulatory Affairs in the pharmaceutical industry: from drug development to commercialization

GAMP categories for computerized systems: what are they and what are they for?

Analytical Method Validation

EUDRALEX Volume 4 Annex 11 Compliance Checklist

From V-model to Agile: how to embrace automation as part of the computerized system validation approach

Innovations in ATMP: state of the industry in 2024

Optimizing pharmacovigilance for a biotechnology leader

Ensuring timely launch: QbD Group's role in establishing a hemophilia drug production line

Ensuring pharmaceutical production quality: cleaning validation for government agency

Revolutionizing pharmacovigilance: a success story of strategic partnership and seamless integration

Patient Support Program (PSP)

IVDR Compliance for Large-Panel Next-Generation Sequencing (NGS) Devices: A Strategic Guide

Patient Enrolment and Retention in Clinical Trials: How to Improve Recruitment and Keep Patients Engaged

Clinical Trial Site Selection and Qualification: A Practical Guide

Risk Management in Clinical Trials: Assessment & Mitigation Strategies

Establishing and Maintaining the Right Level of Clinical Evidence under the EU IVDR

A Decade of Excellence: Linguistic Review Support for a Global Pharma Leader